Caffeine or Theacrine: What's the Difference

Theacrine is marketed as "caffeine without tolerance." The editorial team compared the two substances - by chemical structure, mechanism of action, pharmacokinetics and evidence - and explained what in this marketing has a scientific basis and what does not yet.

Relatives from the purine family

Caffeine is the most widespread psychoactive substance in the world and one of the best-studied sports supplements. Theacrine is a far less known "relative" that has appeared in recent years in pre-workout complexes and fat burners under trade names such as TeaCrine. Manufacturers present it as "caffeine without tolerance." The editorial team checked how well this matches the data.

Chemically both substances belong to the purine alkaloids. Caffeine is 1,3,7-trimethylxanthine. Theacrine is 1,3,7,9-tetramethyluric acid: its molecule has an additional methyl group and one more oxygen atom, meaning it is a derivative not of xanthine but of uric acid.

The natural sources also differ. Caffeine is contained in coffee, tea, cocoa, guarana and mate. Theacrine has been found in significant amounts in the Chinese tea "kucha" (Camellia assamica var. kucha), as well as in minor amounts in some other plants, in particular cupuacu. In plants caffeine is probably a precursor of theacrine.

Such structural closeness explains why the substances are partly similar in action, and the differences in the substituents explain why their pharmacology is not identical.

Mechanism of action: where they coincide and where they differ

The main mechanism of caffeine is well known: it blocks adenosine receptors A1 and A2A in the brain. Adenosine accumulates over the course of the day and signals fatigue; by blocking it, caffeine reduces the feeling of tiredness and effort and increases alertness. Other effects - calcium release, phosphodiesterase inhibition - require concentrations far higher than the usual ones.

Theacrine, according to animal studies, also acts as an antagonist of adenosine receptors. In the 2012 work by Feduccia and colleagues on rats, its stimulating effect on motor activity was shown to depend on both adenosine and dopamine D1/D2 receptors. There are far fewer direct data on the receptor pharmacology of theacrine in humans.

The key claimed difference is tolerance. Regular caffeine intake leads to partial tolerance: the number of adenosine receptors increases and the effect weakens. For theacrine, an 8-week study by Taylor and colleagues in 2016 found no signs of tolerance across a range of measures, which gave grounds to call it "non-adaptogenic."

At the same time it is worth understanding the limitations: this is one small study conducted with the manufacturer's involvement, and "absence of tolerance" was assessed by subjective scales of energy and focus. Definitive conclusions require independent replication.

Pharmacokinetics and interaction

Caffeine is absorbed quickly: the peak plasma concentration is reached about 30-60 minutes later. The half-life in healthy adults is usually a few hours (3-6 hours is most often cited) and depends heavily on the activity of the CYP1A2 enzyme, smoking, pregnancy and hormonal contraceptive use.

Theacrine, according to pharmacokinetic studies in humans, is eliminated more slowly than caffeine. Interestingly, the 2017 study by He and colleagues showed that simultaneous caffeine intake raises the plasma level of theacrine and prolongs its stay in the body, whereas theacrine does not significantly affect the pharmacokinetics of caffeine.

This is precisely why in commercial products theacrine is often combined with caffeine: it is believed that caffeine provides a fast start while theacrine prolongs the feeling of energy. However, whether such a combination delivers a better athletic result than caffeine alone has not been convincingly proven.

• Caffeine: fast onset of action, a well-predictable effect, pronounced individual variability of metabolism.
• Theacrine: slower elimination, less human data, possible interaction with caffeine.

Comparison table

The main differences worth knowing are brought together in the table below. We emphasize: the level of evidence for the two substances is incomparable.

On anti-doping status: caffeine has not been banned since 2004 but is on the WADA monitoring program. Theacrine is not separately mentioned in the Prohibited List; however, the stimulants section contains wording about substances with a similar chemical structure or biological action. Athletes who undergo control should check the status with their national anti-doping organization.

For athletic effectiveness the difference is striking: caffeine has dozens of meta-analyses summarized in the 2020 "umbrella" review by Grgic and colleagues, whereas for theacrine there are only a handful of separate randomized studies with objective performance measures.

So theacrine can be called an "analogue" of caffeine only by chemical kinship, not by the volume of evidence.

Safety and unknowns

For caffeine the safety limits are well defined. EFSA considers that for healthy adults intake of up to 400 mg per day is not a concern, and single doses of up to 200 mg are safe even right before physical exercise. For pregnant women it is recommended not to exceed 200 mg per day.

The side effects of caffeine at excessive doses are well known: anxiety, tremor, tachycardia, insomnia, stomach discomfort. Concentrated caffeine powders are dangerous because of the risk of accidental overdose - fatal cases have been described, so the editorial team categorically advises against such products.

For theacrine the safety data are limited mainly to Taylor's 2016 study: 8 weeks of taking 200-300 mg per day did not lead to clinically significant changes in blood biochemistry, lipids, heart rate or blood pressure. There are no data on long-term use, use during pregnancy or interaction with medications.

So the main difference in safety is not that theacrine is more dangerous, but that simply much less is known about it. People with cardiovascular disease, anxiety disorders, or those taking medications should discuss any stimulant with a doctor.

Editorial conclusions

Caffeine and theacrine are chemical relatives from the purine family, but caffeine is a methylxanthine, while theacrine is a derivative of uric acid with a somewhat different action profile.

The claimed advantage of theacrine - the absence of tolerance - rests on limited data obtained with the manufacturer's involvement. The effectiveness of caffeine for sport, by contrast, is confirmed by dozens of meta-analyses.

Theacrine can be regarded as an interesting but under-researched substance. If you need a proven ergogenic effect, caffeine in moderate doses remains the benchmark.

To continue the topic we recommend our articles on tolerance to caffeine, on the genetics of caffeine metabolism (CYP1A2) and on the composition of pre-workout complexes.

References

1. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51(1):83–133.
2. Feduccia AA, Wang Y, Simms JA, et al. Locomotor activation by theacrine, a purine alkaloid structurally similar to caffeine: involvement of adenosine and dopamine receptors. Pharmacol Biochem Behav. 2012;102(2):241–248.
3. Taylor L, Mumford P, Roberts M, et al. Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use. J Int Soc Sports Nutr. 2016;13:2.
4. He H, Ma D, Crone LB, et al. Assessment of the drug–drug interaction potential between theacrine and caffeine in humans. J Caffeine Res. 2017;7(3):95–102.
5. Guest NS, VanDusseldorp TA, Nelson MT, et al. International society of sports nutrition position stand: caffeine and exercise performance. J Int Soc Sports Nutr. 2021;18(1):1.
6. Grgic J, Grgic I, Pickering C, et al. Wake up and smell the coffee: caffeine supplementation and exercise performance — an umbrella review of 21 published meta-analyses. Br J Sports Med. 2020;54(11):681–688.
7. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the safety of caffeine. EFSA Journal. 2015;13(5):4102.
8. World Anti-Doping Agency. The 2024 Monitoring Program. Montreal: WADA; 2024.